FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes.

Trial Profile

FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2012

At a glance

  • Drugs Atorvastatin; Varespladib
  • Indications Acute coronary syndromes
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms FRANCIS-ACS
  • Sponsors Anthera Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 May 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 24 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top